Regen BioPharma Files New Composition of Matter Patent Application

Regen BioPharma has filed a patent application covering composition of matter and methods of use related to molecules identified in its small molecule program that activate NR2F6 ("Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans").

As previously noted by the company, NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. Based upon the Company's screening programs for treating autoimmune diseases such as Lupus, the data gathered provided support for the filing of this patent application.

Additionally, the company is moving forward with its NR2F6 antagonist small molecule program designed to unleash the cancer-killing potential of a patient's own immune system.

"The patent application lists molecules that activate NR2F6. As we continue to develop our small molecule program, we learn more about the molecular structures key to activating NR2F6 and develop more optimized compounds," said Harry Lander, Ph.D., President and Chief Scientific Officer of Regen. "Thus, we continue to file for patent protection for these unique molecules."

-----------------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.